IL305791A - Salt and solid forms of kinase inhibitor - Google Patents
Salt and solid forms of kinase inhibitorInfo
- Publication number
- IL305791A IL305791A IL305791A IL30579123A IL305791A IL 305791 A IL305791 A IL 305791A IL 305791 A IL305791 A IL 305791A IL 30579123 A IL30579123 A IL 30579123A IL 305791 A IL305791 A IL 305791A
- Authority
- IL
- Israel
- Prior art keywords
- salt
- kinase inhibitor
- solid forms
- solid
- forms
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000003839 salts Chemical group 0.000 title 1
- 239000007787 solid Chemical group 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163159107P | 2021-03-10 | 2021-03-10 | |
| US202163208641P | 2021-06-09 | 2021-06-09 | |
| PCT/US2022/019776 WO2022192558A1 (en) | 2021-03-10 | 2022-03-10 | Salt and solid forms of a kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL305791A true IL305791A (en) | 2023-11-01 |
Family
ID=81074313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL305791A IL305791A (en) | 2021-03-10 | 2022-03-10 | Salt and solid forms of kinase inhibitor |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240254130A1 (https=) |
| EP (1) | EP4305036A1 (https=) |
| JP (1) | JP2024509276A (https=) |
| KR (1) | KR20240013720A (https=) |
| AU (1) | AU2022234314A1 (https=) |
| BR (1) | BR112023018246A2 (https=) |
| CA (1) | CA3211477A1 (https=) |
| CR (1) | CR20230479A (https=) |
| IL (1) | IL305791A (https=) |
| MX (1) | MX2023010606A (https=) |
| WO (1) | WO2022192558A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230391780A1 (en) * | 2020-10-14 | 2023-12-07 | Blueprint Medicines Corporation | Compositions and methods for treating kit- and pdgfra-mediated diseases |
| WO2024171143A1 (en) | 2023-02-17 | 2024-08-22 | Assia Chemical Industries Ltd. | Salts and solid forms of elenestinib |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021020441A2 (pt) | 2019-04-12 | 2021-12-14 | Blueprint Medicines Corp | Derivados de pirrolotriazina para tratar doenças mediadas por kit e pdgfra |
-
2022
- 2022-03-10 JP JP2023555320A patent/JP2024509276A/ja active Pending
- 2022-03-10 IL IL305791A patent/IL305791A/en unknown
- 2022-03-10 CA CA3211477A patent/CA3211477A1/en active Pending
- 2022-03-10 EP EP22714289.0A patent/EP4305036A1/en active Pending
- 2022-03-10 AU AU2022234314A patent/AU2022234314A1/en active Pending
- 2022-03-10 BR BR112023018246A patent/BR112023018246A2/pt unknown
- 2022-03-10 WO PCT/US2022/019776 patent/WO2022192558A1/en not_active Ceased
- 2022-03-10 MX MX2023010606A patent/MX2023010606A/es unknown
- 2022-03-10 US US18/549,769 patent/US20240254130A1/en active Pending
- 2022-03-10 CR CR20230479A patent/CR20230479A/es unknown
- 2022-03-10 KR KR1020237034550A patent/KR20240013720A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240254130A1 (en) | 2024-08-01 |
| EP4305036A1 (en) | 2024-01-17 |
| BR112023018246A2 (pt) | 2024-01-30 |
| JP2024509276A (ja) | 2024-02-29 |
| CA3211477A1 (en) | 2022-09-15 |
| AU2022234314A1 (en) | 2023-09-28 |
| MX2023010606A (es) | 2023-10-19 |
| KR20240013720A (ko) | 2024-01-30 |
| CR20230479A (es) | 2024-03-08 |
| WO2022192558A1 (en) | 2022-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202105949RA (en) | Crystalline forms and salt forms of a kinase inhibitor | |
| IL290106B1 (en) | Crystalline form of ATR inhibitor and its use | |
| ZA202303655B (en) | Solid forms of a cdk4 inhibitor | |
| SG11202109438TA (en) | A salt and crystal form of a fak inhibitor | |
| ZA202212146B (en) | Inhibitors of nek7 kinase | |
| HUE069889T2 (hu) | Belumoszudil és belumoszudil-sók szilárd formái | |
| IL310234A (en) | Salts and solid-state configurations of a KIF18A inhibitory compound | |
| IL313548A (en) | MET kinase inhibitors | |
| IL288484A (en) | Crystalline salt forms of a kinase inhibitor | |
| IL305791A (en) | Salt and solid forms of kinase inhibitor | |
| IL313735A (en) | Salts and solid forms of Pajfer inhibitor and processes for their preparation | |
| SG11202102110PA (en) | Novel hydrochloride salt forms of a sulfonamide structured kinase inhibitor | |
| HUE068724T2 (hu) | Transzglutaminázok inhibitorai | |
| IL297684B1 (en) | Processes for preparing a kinase inhibitor | |
| IL311588A (en) | LPXC inhibitors and their uses | |
| HUE068818T2 (hu) | Transzglutamináz inhibitorok | |
| HK40106448A (en) | Salt and solid forms of a kinase inhibitor | |
| EP4161488A4 (en) | RHO-KINASE INHIBITOR RELEASING IMPLANTS AND RELATED METHODS OF USE | |
| HK40117256A (en) | Crystalline forms and salt forms of a kinase inhibitor | |
| PL4192812T3 (pl) | Inhibitory transglutaminaz | |
| GB202107612D0 (en) | Inhibitors of metallo-beta-lactamases | |
| HK40074144A (en) | Crystalline salt forms of a kinase inhibitor | |
| IL321700A (en) | Salts and solid forms of sonrotoclax intermediate | |
| GB202203181D0 (en) | Inhibitors of elF4A | |
| HK40057598A (en) | Novel hydrochloride salt forms of a sulfonamide structured kinase inhibitor |